Likewise, in another study, patients with p16/CDKN2A deficient imatinib/sunitinib-resistant gastrointestinal stromal tumor have no significant clinical benefits of Palbociclib monotherapy [52]. Here, CDKN2A is linked to gastrointestinal stromal tumor.